Lucira Health, Inc. (LHDX): Price and Financial Metrics
GET POWR RATINGS... FREE!
LHDX Stock Price Chart Interactive Chart >
LHDX Price/Volume Stats
|Current price||$7.88||52-week high||$37.99|
|Prev. close||$7.90||52-week low||$4.23|
|Day high||$8.19||Avg. volume||1,327,841|
|50-day MA||$8.78||Dividend yield||N/A|
|200-day MA||$0.00||Market Cap||304.95M|
Lucira Health, Inc. (LHDX) Company Bio
Lucira Health, Inc. produces and distributes medical equipment. The Company offers disposable test kits to detect DNA and RNA of infectious diseases. Lucira Health markets its products in the United States.
Most Popular Stories View All
LHDX Latest News Stream
|Loading, please wait...|
LHDX Latest Social Stream
View Full LHDX Social Stream
Latest LHDX News From Around the Web
Below are the latest news stories about Lucira Health Inc that investors may wish to consider to help them evaluate LHDX as an investment opportunity.
EMERYVILLE, Calif., August 23, 2021--Lucira Health, Inc. ("Lucira Health" or "Lucira") (NASDAQ: LHDX), a medical technology company focused on the development and commercialization of transformative and innovative infectious disease test kits, today announced life science professional Ghazi Kashmolah has joined the company as Chief Quality Officer and Executive Vice President Regulatory Affairs.
Volatility comes with the territory when you invest in biotech stocks. Here's why they chose Bluebird Bio (NASDAQ: BLUE), Lucira Health (NASDAQ: LHDX), and Vertex Pharmaceuticals (NASDAQ: VRTX). Prosper Junior Bakiny (Bluebird Bio): Shares of Bluebird Bio have been hammered in recent years.
After the speakers' presentation, there will be a question-and-answer session [Operator instructions] I would now like to hand the conference over to your first speaker today, Hannah Jeffrey from Gilmartin Group. Earlier today, Lucira Health released financial results for the second quarter ended June 30, 2021. Joining me today on today's call are Erik Engelson, president and chief executive officer; and Dan George, chief financial officer.
EMERYVILLE, Calif., Aug. 12, 2021 (GLOBE NEWSWIRE) -- Lucira Health, Inc. (Nasdaq: LHDX) ("Lucira Health," "Lucira" or the "Company"), a medical technology company focused on the development and commercialization of transformative and innovative infectious disease test kits, today reported financial results for the second quarter ended June 30, 2021. Recent Highlights Recorded record-high revenue of $12.4 million for the second quarter of 2021, representing 175% sequential growth from the previo
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
LHDX Price Returns